Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Martín Lázaro
Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib
Lung Cancer Management
Related publications
Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib
Journal of Community and Supportive Oncology
Oncology
Hematology
The Potential Role of HGF-MET Signaling and Autophagy in the War of Alectinib Versus Crizotinib Against ALK-positive NSCLC
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pcn82 - Budget Impact Analysis of Alectinib for the Treatment of Patients With Untreated Alk-Rearranged NSCLC in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient
Molecular and Clinical Oncology
Cancer Research
Oncology